

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Neuland to open commercial peptide facility as part of planned phased expansion

09 March 2026 | News

CDMO's Module 1 commercial production facility to be operational by summer 2026



Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus in Telangana, with further capacity expansions planned as client demand increases.

The first of four planned modules is expected to be operational by the summer of this year, adding commercial-scale capabilities to Neuland's existing clinical stage S-Block facilities. Module one has secured firm commitments of approximately \$30 million.

Once open, Module One will provide 6,370 L of SPPS [solid phase peptide synthesis] and LPPS [liquid phase peptide synthesis] reactor capacity – for sizes of 250 L to 3000 L in LPPS, as well as SPPS reactors up to the 500 L scale.

Construction of the facility began last year and will enable client execution from small-scale to multi-ton commercial volumes, while also providing the flexibility needed for complex and long-chain peptide programmes.

With GLP-1 manufacturing consuming a growing share of global peptide capacity, Neuland is targeting innovator and emerging biotech programs facing tightening access to clinical and commercial manufacturing across a broad range of indications.

R&D headcount is also expected to grow at a double-digit rate this year, and the manufacturing team will more than double to support the ramp-up. This complements Neuland's existing 1,174,000 L of API manufacturing capacity across three US FDA-approved facilities, which are supported by a large, dedicated R&D Centre located in close proximity. This integrated setup enables seamless scale-up, rapid tech transfer, and highly efficient development-to-commercial execution.

The newly completed plants will feature advanced digital operation systems – controlled through DCS-based automation with eBMR integration – and scalable peptide technologies across synthesis, purification and drying. The facility includes expanded downstream capabilities: multi-column prep-HPLC systems, lyophilisers and dryers sized for commercial campaigns, enhanced solvent handling and tank farm infrastructure, dedicated warehouses, and upgraded waste management systems supporting high-volume operations. The systems are designed to support data-rich process development, reduced batch variability and improved cycle times.